Cantor Fitzgerald raises the price target for Ultragenyx Pharmaceutical to $115.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its target price increased by research analysts at Cantor Fitzgerald from $107.00 to $115.00 in a research report issued on Friday…

Read More: https://www.tickerreport.com/banking-finance/12078225/cantor-fitzgerald-increases-ultragenyx-pharmaceutical-nasdaqrare-price-target-to-115-00.html